APA (7th ed.) Citation

Shi, Y., Ba, Y., Wang, J., Xiong, J., Gu, K., Chen, Y., . . . Hou, S. First-line treatment of anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus FOLFIRI alone in Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer: A randomized, phase 3 trial. Nature Publishing Group.

Chicago Style (17th ed.) Citation

Shi, Yuankai, et al. First-line Treatment of Anti-EGFR Monoclonal Antibody Cetuximab β Plus FOLFIRI Versus FOLFIRI Alone in Chinese Patients with RAS/BRAF Wild-type Metastatic Colorectal Cancer: A Randomized, Phase 3 Trial. Nature Publishing Group.

MLA (9th ed.) Citation

Shi, Yuankai, et al. First-line Treatment of Anti-EGFR Monoclonal Antibody Cetuximab β Plus FOLFIRI Versus FOLFIRI Alone in Chinese Patients with RAS/BRAF Wild-type Metastatic Colorectal Cancer: A Randomized, Phase 3 Trial. Nature Publishing Group.